The Regeneration Center coordinates records review, physician consultation and regenerative-medicine services in Bangkok. A consultation considers the diagnosis, current care, imaging, laboratory findings and the evidence for the actual cell preparation. Eligibility, possible benefit and treatment risks require an individual assessment.
The center has operated since 2007. Its care pathway brings together clinical facilities, laboratory preparation and follow-up. A facility license or a quality-control process concerns a defined activity; it does not establish that every offered intervention is effective for every listed condition.
Cell sources and preparations differ. Peripheral-blood progenitor cells, bone-marrow preparations, cord-blood cells and mesenchymal stromal cells are not interchangeable treatments. Radiology, genetic testing, immune evaluation and cell banking may form part of a proposed care pathway when relevant to the individual case.
Hematopoietic stem-cell transplantation has established uses in selected blood and immune disorders. That evidence cannot be transferred automatically to other cell preparations or to proposed repair of the heart, lungs, kidneys or nervous system. Review the intervention, the studied population, meaningful outcomes and adverse events separately.
Cellular-therapy evaluation brings together the diagnosis, medical history, current treatment, imaging, laboratory findings and the evidence relevant to the requested condition. That review helps the medical team decide whether a consultation is appropriate and which questions must be resolved before a protocol can be considered.
Since 2007, the center has coordinated regenerative-medicine inquiries through a Bangkok network of licensed clinical facilities and quality-controlled laboratory services. The care pathway connects records review, physician consultation, diagnostics, cell preparation and follow-up while keeping every decision tied to the individual case.
Autologous and allogeneic cell sources are not interchangeable products. Source selection, laboratory preparation, route and supporting care depend on the clinical question, health status and available evidence. Functional-medicine review, radiology, genetic testing, immune evaluation and cell banking can be incorporated when they add useful clinical context.
The long clinical history of hematopoietic stem-cell transplantation sits alongside newer, still-evolving applications of cellular medicine. Our role is to separate established practice from investigational use, review the evidence for the specific diagnosis and explain uncertainty, alternatives and eligibility in language patients and families can use.
Explore four frequently requested pathways. Each opens into condition-specific information and begins with medical-record review rather than a preset treatment package.
Digestive and liver conditions include different diseases with different treatment needs. Information about liver disease, Type 1 diabetes, Type 2 diabetes, diabetic nephropathy, pancreatitis, and Crohn's disease or ulcerative colitis should be read in that diagnosis-specific context. The presence of stem cells in a tissue does not show that an infused mesenchymal preparation reverses disease. Assessment should identify the actual product, clinical evidence and appropriate standard care.
Kidney stem cell therapy is being investigated for renal conditions. Changes in inflammatory signaling, including the paracrine effect, do not by themselves establish replacement of kidney tissue, restored filtration or an alternative to dialysis or transplantation. Evidence for one kidney diagnosis does not establish benefit in polycystic kidney disease or another disorder. Review eligibility, kidney-function measurements, follow-up and risks alongside existing renal care.
Orthopedic assessment distinguishes knee injuries, arthritic hips, shoulder injuries, sports injuries, cartilage, ligament and tendon injuries, degenerative disc disease, and osteoarthritis. Cell-based procedures differ in preparation, route and evidence. A proposed repair mechanism does not establish restored cartilage, elimination of pain or avoidance of otherwise indicated surgery. Diagnosis, rehabilitation and comparison with appropriate nonsurgical and surgical care remain central to a treatment decision.
Regenerative medicine and age-management therapies involve different proposed interventions and outcomes. The properties of multipotent stem cells do not establish longer life, improved vitality or visible rejuvenation within one or two weeks. Evidence about breast reconstruction does not demonstrate a general anti-aging benefit. Discuss the intended outcome, supporting human evidence, procedural risks, alternatives and follow-up before deciding on a program.
Personalized care begins with a confidential review of your medical history.
Autologous and allogeneic describe where the cells come from. They do not describe a condition, outcome or one-size-fits-all treatment.
Cells are collected from the patient, prepared for the intended clinical pathway and returned under physician supervision. Collection method, cell yield and suitability depend on health status and the treatment objective.
Autologous preparation can involve peripheral-blood progenitor cells, bone-marrow-derived cells or adipose-derived cells. Before collection, the team reviews current medication, infection risk, blood counts, anesthesia or procedure considerations and whether the patientβs own cells are appropriate for the intended application.
Cells are derived from screened donor tissue and expanded or prepared through a controlled laboratory pathway. Source selection depends on the condition, available evidence, quality controls and physician review.
Donor-derived preparations may originate from umbilical-cord tissue, Whartonβs jelly, placental tissue, dental pulp or other screened sources. The laboratory pathway, release criteria, compatibility considerations, intended route and follow-up plan are reviewed as part of the complete protocol. They are not treated as interchangeable product labels.
Cell source, dose, route and supporting care are determined only after a physician reviews the diagnosis, medical history, test results and current treatment.
Select a medical specialty to learn more about the conditions we evaluate and treat, their clinical significance, and the level of assessment and treatment information available through our center.
Cancer care depends on the cancer type, stage, biomarkers, previous treatment and the patient's health. Blood-forming stem-cell transplantation, immune-cell treatments, surgery and other oncology procedures serve different purposes. Evidence for a transplant in a selected blood cancer cannot establish benefit from a different cell product in a solid tumor. Review any proposed addition to treatment with the oncology team, including the product, clinical evidence, risks and interaction with standard care.
Heart failure, coronary artery disease and peripheral vascular disease are different clinical problems. Proposed cell-based approaches should be evaluated for the actual diagnosis, preparation, route and measured outcomes. Laboratory cardiomyocyte-like properties or cell-signaling effects do not establish replacement of heart muscle, pacemaker cells or damaged vessels in patients. Continue assessment of medicines, devices and procedures with the treating cardiology team.
COPD, emphysema and pulmonary fibrosis differ in their causes, course and treatment. Cell-based approaches are under investigation; a proposed effect on inflammation does not establish growth of new lung tissue or an alternative to an indicated transplant. Lung-function measurements, symptoms, exacerbations, follow-up and adverse events require intervention-specific assessment. Existing respiratory care and any transplant advice need individual specialist review.
Brain and spinal-cord conditions differ in their causes, affected structures and treatment needs. Neural, mesenchymal and blood-forming cell preparations are different products. Laboratory neural differentiation does not establish restored neurological function in autism, cerebral palsy, stroke, ALS or a spinal injury. Consider the actual diagnosis, preparation, human evidence, rehabilitation needs and procedure-specific risks with the treating specialist.
Everything your treatment journey needs, in one center.
Begin with a confidential review of your diagnosis, current care and medical records. The team will explain what can be assessed remotely, what additional information may be needed and whether a physician consultation is an appropriate next step.
Our team evaluates neurological, orthopedic, cardiovascular, liver, kidney, lung, autoimmune and other degenerative conditions. Suitability depends on an individual medical review.
The coordination team organizes the available history, imaging and test results for medical review. If more information is needed, you will receive a clear request before a consultation is arranged.
Protocols may involve autologous or allogeneic cell sources. The selected source depends on the condition, medical history, available evidence and physician review.
Recommendations are individualized to the diagnosis, medical history, test results, current care and treatment goals rather than selected from a preset package.
Submit your medical records for a confidential evaluation. The medical team will advise whether further consultation or treatment may be appropriate.
Evidence-informed articles on regenerative medicine, cellular therapies and patient care.
Make this page easier to read and navigate. Your choices stay on this device.
No adjustments activeReady to read this page.
Speech uses a voice already installed on your device. SCT does not receive or store what is spoken. Keep browser-service voices off when you require on-device processing.
How we support access and how to contact us.
We want every visitor to stemcellthailand.org to be able to find, read and act on the information here. That includes people who browse with assistive technology and people who need to change how a page looks before they can read it comfortably.
We treat accessibility as continuing maintenance rather than a one time project. We use the Web Content Accessibility Guidelines (WCAG) as our working reference and review accessibility during design, development and content review.
We do not claim that every page meets every guideline at all times. Parts of this site carry older medical content, embedded video or third-party services whose behavior sits outside our direct control. Where we find a barrier, we fix it and record the fix.
The panel on this site runs entirely in your browser. It can:
Reading aloud is a convenience for visitors who do not use assistive technology. It is not a screen reader. If you use VoiceOver, TalkBack, Narrator, NVDA or JAWS, those remain the right way to browse this site, and our work goes into the underlying page structure so they perform well. A settings panel cannot substitute for accessible markup, and we do not present it as one.
The panel creates no account, sets no tracking cookie and sends no reading preference to us. Your choices are stored in your own browser and stay on your device. Spoken reading uses the speech voices your browser or operating system already provides, so we never receive or store what is read aloud.
If you meet an accessibility barrier, or you need information from this site in another format, email info@stemcellthailand.org. Tell us the page you were on and what you were trying to do. We aim to reply within three to five business days, and we can provide the information through another channel where that helps.
Please do not include private medical details in an accessibility request.
